UniQure pauses dosing in Fabry disease trial amid safety concerns
UniQure has ceased dosing in two cohorts in a Phase I/IIa trial of its adeno-associated viral (AAV) gene therapy, AMT-191,…
UniQure has ceased dosing in two cohorts in a Phase I/IIa trial of its adeno-associated viral (AAV) gene therapy, AMT-191,…